ORBIMED ADVISORS LLC - 31 Dec 2024 SCHEDULE 13G Report for ADC Therapeutics SA Common Shares, par value CHF 0.08 per share (ADCT)

Filing Manager
ORBIMED ADVISORS LLC
Reporting Manager
ORBIMED CAPITAL LLC
Security
ADC Therapeutics SA Common Shares, par value CHF 0.08 per share
Symbol
ADCT
Shares outstanding
95,494,806 shares
Disclosed Ownership
3,437,813 shares
Ownership
3.6%
Form type
SCHEDULE 13G
Filing time
14 Feb 2025, 16:35:24 UTC
Date of event
31 Dec 2024
Next filing
17 Feb 2026
SEC
View on sec.gov

Quoteable Key Fact

"ORBIMED ADVISORS LLC disclosed 3.6% ownership in ADC Therapeutics SA Common Shares, par value CHF 0.08 per share (ADCT) on 31 Dec 2024."

Quick Takeaways

  • ORBIMED ADVISORS LLC filed SCHEDULE 13G for ADC Therapeutics SA Common Shares, par value CHF 0.08 per share (ADCT).
  • Disclosed ownership: 3.6%.
  • Date of event: 31 Dec 2024.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 14 Feb 2025, 16:35.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (2)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
ORBIMED ADVISORS LLC 2.6% 2,530,638 0 2,530,638 /s/ Carl L. Gordon Carl L. Gordon/Member
ORBIMED CAPITAL LLC 3.6% 3,437,813 3,437,813 0 /s/ Carl L. Gordon Carl L. Gordon/Member